Efficacy and imaging evaluation of 177Lu-labeled antibody-drug conjugates as a potential theranostic agent for HER2-positive breast cancer

被引：0
|
作者：
Kim, Heejung [1 ]
Shin, Eunbi [1 ]
Lee, JooHyun [1 ]
Yoo, Ran Ji [1 ]
Park, Jang Woo [1 ]
Chung, Hye Kyung [1 ]
Shim, Jae-Hoon [1 ]
机构：
[1] Korea Inst Radiol & Med Sci KIRAMS, Seoul, South Korea
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2021年 / 96-97卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
SP-124
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [21] Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates
    Yan, Ying
    Li, Qiao
    Li, Jianbin
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [22] A second-generation antibody-drug conjugate to treat HER2-positive breast cancer
    Rassy, Elie
    Delaloge, Suzette
    LANCET, 2023, 401 (10371): : 80 - 81
  • [23] Evaluation of a Novel and Highly Efficacious Anti-HER2 Antibody-Drug Conjugate for HER2-Positive Breast Cancer Treatment
    Vuist, I.
    Oswald, E.
    Koehler, C.
    Sauter, P.
    Eades-Perner, A. M.
    Williams, C.
    Schueler, J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S74 - S74
  • [24] Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts
    Abbas, Nasir
    Bruland, Oyvind Sverre
    Brevik, Ellen Mengshoel
    Dahle, Jostein
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (08) : 838 - 847
  • [25] Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma
    Shih, Chia-Hsien
    Lin, Yu-Hua
    Luo, Hao-Lun
    Sung, Wen-Wei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [26] Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates
    Gianolio, Diego A.
    Rouleau, Cecile
    Bauta, William E.
    Lovett, Dennis
    Cantrell, William R., Jr.
    Recio, Antonio, III
    Wolstenholme-Hogg, Paul
    Busch, Michelle
    Pan, Peng
    Stefano, James E.
    Kramer, Hildegard M.
    Goebel, James
    Krumbholz, Roy D.
    Roth, Stephanie
    Schmid, Steven M.
    Teicher, Beverly A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (03) : 439 - 449
  • [27] Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis
    Kang, Zian
    Jin, Yuqing
    Yu, Huihui
    Li, Su
    Qi, Yingjie
    BMC CANCER, 2024, 24 (01)
  • [28] Development of next-generation antibody-drug conjugates for resistant HER2-positive tumors
    Lacasse, Vincent
    Leyton, Jeffrey V.
    Beaudoin, Simon
    Barok, Mark
    Joensuu, Heikki
    CANCER RESEARCH, 2018, 78 (13)
  • [29] Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?
    Nicolo, Eleonora
    Repetto, Matteo
    Bielo, Luca Boscolo
    Tarantino, Paolo
    Curigliano, Giuseppe
    CANCER JOURNAL, 2022, 28 (06): : 436 - 445
  • [30] Statin therapy enhances the efficacy of HER2 directed antibody-drug conjugates in breast cancer
    Liu, Bo
    Drago, Joshua Z.
    Rao, Yi
    Pereira, Patricia R.
    Safonov, Anton
    Marra, Antonio
    Ahmed, Mehnaj S.
    Modi, Shanu
    Reis-Filho, Jorge S.
    Montemurro, Filippo
    Razavi, Pedram
    Lewis, Jason S.
    Chandarlapaty, Sarat
    CANCER RESEARCH, 2022, 82 (12)
12345